The association between plasma miR-122-5p release pattern at admission and all-cause mortality or shock after out-of-hospital cardiac arrest.


Journal

Biomarkers : biochemical indicators of exposure, response, and susceptibility to chemicals
ISSN: 1366-5804
Titre abrégé: Biomarkers
Pays: England
ID NLM: 9606000

Informations de publication

Date de publication:
Feb 2019
Historique:
pubmed: 18 7 2018
medline: 7 8 2019
entrez: 18 7 2018
Statut: ppublish

Résumé

Data suggests that the plasma levels of the liver-specific miR-122-5p might both be a marker of cardiogenic shock and a prognostic marker of out-of-hospital cardiac arrest (OHCA). Our aim was to characterize plasma miR-122-5p at admission after OHCA and to assess the association between miR-122-5p and relevant clinical factors such all-cause mortality and shock at admission after OHCA. In the pilot trial, 10 survivors after OHCA were compared to 10 age- and sex-matched controls. In the main trial, 167 unconscious survivors of OHCA from the Targeted Temperature Management (TTM) trial were included. In the pilot trial, plasma miR-122-5p at admission after OHCA was 400-fold elevated compared to controls. In the main trial, plasma miR-122-5p at admission was independently associated with lactate and bystander cardiopulmonary resuscitation. miR-122-5p at admission was not associated with shock at admission (p = 0.14) or all-cause mortality (p = 0.35). Target temperature (33 °C vs 36 °C) was not associated with miR-122-5p levels at any time point. After OHCA, miR-122-5p demonstrated a marked acute increase in plasma and was independently associated with lactate and bystander resuscitation. However, miR-122-5p at admission was not associated with all-cause mortality or shock at admission.

Sections du résumé

BACKGROUND BACKGROUND
Data suggests that the plasma levels of the liver-specific miR-122-5p might both be a marker of cardiogenic shock and a prognostic marker of out-of-hospital cardiac arrest (OHCA). Our aim was to characterize plasma miR-122-5p at admission after OHCA and to assess the association between miR-122-5p and relevant clinical factors such all-cause mortality and shock at admission after OHCA.
METHODS METHODS
In the pilot trial, 10 survivors after OHCA were compared to 10 age- and sex-matched controls. In the main trial, 167 unconscious survivors of OHCA from the Targeted Temperature Management (TTM) trial were included.
RESULTS RESULTS
In the pilot trial, plasma miR-122-5p at admission after OHCA was 400-fold elevated compared to controls. In the main trial, plasma miR-122-5p at admission was independently associated with lactate and bystander cardiopulmonary resuscitation. miR-122-5p at admission was not associated with shock at admission (p = 0.14) or all-cause mortality (p = 0.35). Target temperature (33 °C vs 36 °C) was not associated with miR-122-5p levels at any time point.
CONCLUSIONS CONCLUSIONS
After OHCA, miR-122-5p demonstrated a marked acute increase in plasma and was independently associated with lactate and bystander resuscitation. However, miR-122-5p at admission was not associated with all-cause mortality or shock at admission.

Identifiants

pubmed: 30015516
doi: 10.1080/1354750X.2018.1499804
doi:

Substances chimiques

MIRN122 microRNA, human 0
MicroRNAs 0
Lactic Acid 33X04XA5AT

Types de publication

Clinical Trial Journal Article

Langues

eng

Pagination

29-35

Auteurs

Patrik Gilje (P)

a Department of Cardiology, Clinical Sciences , Lund University , Lund , Sweden.

Martin Frydland (M)

b The Heart Centre, Department of Cardiology , Copenhagen University Hospital , Copenhagen , Denmark.

John Bro-Jeppesen (J)

b The Heart Centre, Department of Cardiology , Copenhagen University Hospital , Copenhagen , Denmark.

Josef Dankiewicz (J)

c Department of Intensive and Perioperative Care, Clinical Sciences , Lund University , Lund , Sweden.

Hans Friberg (H)

c Department of Intensive and Perioperative Care, Clinical Sciences , Lund University , Lund , Sweden.

Malin Rundgren (M)

c Department of Intensive and Perioperative Care, Clinical Sciences , Lund University , Lund , Sweden.

Yvan Devaux (Y)

d Cardiovascular Research Unit , Luxembourg Institute of Health , Luxembourg , Luxembourg.

Pascal Stammet (P)

e The Medical Department, National Rescue Services , Luxembourg, Luxembourg.

Mariam Al-Mashat (M)

f Department of Clinical Physiology, Clinical Sciences , Lund University , Lund , Sweden.

Jonas Jögi (J)

f Department of Clinical Physiology, Clinical Sciences , Lund University , Lund , Sweden.

Jesper Kjaergaard (J)

b The Heart Centre, Department of Cardiology , Copenhagen University Hospital , Copenhagen , Denmark.

Christian Hassager (C)

b The Heart Centre, Department of Cardiology , Copenhagen University Hospital , Copenhagen , Denmark.

David Erlinge (D)

a Department of Cardiology, Clinical Sciences , Lund University , Lund , Sweden.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH